Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.

Rickards KJ, Page CP, Lees P, Gettinby G, Cunningham FM.

J Vet Pharmacol Ther. 2003 Apr;26(2):123-30.

PMID:
12667182
2.

Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.

Rickards KJ, Page CP, Lees P, Cunningham FM.

J Vet Pharmacol Ther. 2001 Aug;24(4):275-81.

PMID:
11555183
3.

Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.

Tang HF, Lu JJ, Tang JF, Zheng X, Liang YQ, Wang XF, Wang YJ, Mao LG, Chen JQ.

Int Immunopharmacol. 2010 Apr;10(4):406-11. doi: 10.1016/j.intimp.2010.01.003. Epub 2010 Jan 13.

PMID:
20074667
4.

Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.

Pruniaux MP, Lagente V, Ouaged M, Bertin B, Moreau F, Julien-Larose C, Rocher MN, Leportier C, Martin B, Bouget A, Dubuit JP, Burnouf C, Doherty AM, Bertrand CP.

Fundam Clin Pharmacol. 2010 Feb;24(1):73-82. doi: 10.1111/j.1472-8206.2009.00725.x. Epub 2009 Jul 24.

PMID:
19650853
5.
6.
7.

Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.

Rickards KJ, Page CP, Lees P, Cunningham FM.

Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):319-30.

PMID:
11044563
8.

Effects of a MAPK p38 inhibitor on lung function and airway inflammation in equine recurrent airway obstruction.

Lavoie JP, Thompson D, Hamilton E, Debrue M, David F, Hickey G.

Equine Vet J. 2008 Sep;40(6):577-83.

PMID:
19031513
9.

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.

J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

10.
11.

Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.

Germain N, Corbel M, Belleguic C, Boichot E, Lagente V.

Mediators Inflamm. 2001 Jun;10(3):117-23.

12.
13.

Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.

Makhay MM, Houslay MD, O'Donnell JM.

Psychopharmacology (Berl). 2001 Nov;158(3):297-304.

PMID:
11713620
14.

Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.

Oger S, Méhats C, Barnette MS, Ferré F, Cabrol D, Leroy MJ.

Biol Reprod. 2004 Feb;70(2):458-64. Epub 2003 Oct 15.

PMID:
14561639
15.
16.

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM.

Psychopharmacology (Berl). 2005 Oct;182(1):104-15. Epub 2005 Sep 29.

PMID:
16010541
17.

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.

Barnette MS, Underwood DC.

Curr Opin Pulm Med. 2000 Mar;6(2):164-9. Review.

PMID:
10741778
18.

Platelets in equine recurrent airway obstruction.

Hammond A, Bailey SR, Marr CM, Cunningham FM.

Res Vet Sci. 2007 Jun;82(3):332-4. Epub 2006 Nov 14.

PMID:
17107696
19.

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.

J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454. Epub 2009 Jun 4.

20.

Supplemental Content

Support Center